Association of miR-203 Expression with Prognostic Value in Patients with Esophageal Cancer: A Systematic Review and Meta-Analysis

References

• Watanabe M, Suehara N, Koga K, et al. Outcomes of endoscopic submucosal dissection and esophagectomy for early and superficial carcinoma of the esophagus. ESOPHAGUS-TOKYO. 2010;7(4):1–6. doi:10.1007/s10388-010-0249-1.
   Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Watanabe M, Otake R, Kozuki R, et al. Recent progress in multidisciplinary treatment for patients with esophageal cancer. Surg Today. 2020;50(1):12–20. doi:10.1007/s00595-019-01878-7.
   PubMed Web of Science ®Google Scholar
• Xu QL, Li H, Zhu YJ, Xu G. The treatments and postoperative complications of esophageal cancer: a review. J Cardiothorac Surg. 2020;15(1):163. doi:10.1186/s13019-020-01202-2.
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center M, Ferlay J, Forman D. Global cancerstatistics. CA A Cancer Journal for Clinicians. 2011;6(2):169–190.
   Google Scholar
• Galasso M, Sana ME, Volinia S. Non-coding RNAs: a key to future personalized molecular therapy? Genome Med. 2010;2(2):12. doi:10.1186/gm133.
   PubMedGoogle Scholar
• Ali Syeda Z, Langden SSS, Munkhzul C, Lee M, Song SJ. Regulatory mechanism of MicroRNA expression in cancer. Int J Mol Sci. 2020;21(5):1723.
   PubMed Web of Science ®Google Scholar
• Gao S, Zhao ZY, Zhang ZY, Zhang Y, Wu R. Prognostic value of MicroRNAs in esophageal carcinoma: a meta-analysis. Clin Transl Gastroen. 2018;9(11):203.
   PubMedGoogle Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336–341. doi:10.1016/j.ijsu.2010.02.007.
   PubMed Web of Science ®Google Scholar
• Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–605. doi:10.1007/s10654-010-9491-z.
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Sutton AJ, Ioannidis JPA, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343(jul22 1):d4002–d4002. doi:10.1136/bmj.d4002.
   PubMed Web of Science ®Google Scholar
• Okumura T, Shimada Y, Moriyama M, et al. MicroRNA-203 inhibits the progression of esophageal squamous cell carcinoma with restored epithelial tissue architecture in vivo. Int J Oncol. 2014;44(6):1923–1932. doi:10.3892/ijo.2014.2365.
   PubMed Web of Science ®Google Scholar
• Hezova R, Kovarikova A, Srovnal J, et al. Diagnostic and prognostic potential of miR-21, miR-29c, miR-148 and miR-203 in adenocarcinoma and squamous cell carcinoma of esophagus. Diagn Pathol. 2015;10(1):42. doi:10.1186/s13000-015-0280-6.
   PubMedGoogle Scholar
• Liu Y, Dong Z, Liang J, et al. Methylation-mediated repression of potential tumor suppressor miR-203a and miR-203b contributes to esophageal squamous cell carcinoma development. Tumour Biol. 2016;37(4):5621–5632. doi:10.1007/s13277-015-4432-9.
   PubMedGoogle Scholar
• Shao Y, Gu W, Ning Z, et al. Evaluating the prognostic value of microRNA-203 in solid tumors based on a meta-analysis and the cancer genome atlas (tcga) datasets. Cell Physiol Biochem. 2017;41(4):1468–1480. doi:10.1159/000470649.
   PubMedGoogle Scholar
• He R, Wang J, Ye K, et al. Reduced miR-203 predicts metastasis and poor survival in esophageal carcinoma. Aging (Albany NY). 2019;11(24):12114–12130. doi:10.18632/aging.102543.
   PubMedGoogle Scholar
• Qi Q, Ling Y, Zhu M, Zhang Y, Liu Y. Hypermethylation and low expression of miR-203 in patients with esophageal cancer in Chinese population. Int J Clin Exp Pathol. 2016;9(6):6245–6251.
   Web of Science ®Google Scholar
• You A, Fu L, Li Y, Li X, You B. MicroRNA-203 restrains epithelial-mesenchymal transition, invasion and migration of papillary thyroid cancer by downregulating AKT3. Cell Cycle. 2020;19(10):1105–1121. doi:10.1080/15384101.2020.1746490.
   PubMed Web of Science ®Google Scholar
• Zhao F, Wei C, Cui MY, et al. Prognostic value of microRNAs in pancreatic cancer: a meta-analysis. Aging (Albany NY). 2020;12(10):9380–9404. doi:10.18632/aging.103214.
   PubMedGoogle Scholar
• Ahir BK, Lakka SS. Elucidating the microRNA-203 specific biological processes in glioblastoma cells from comprehensive RNA-sequencing transcriptome profiling. Cell Signal. 2019;53:22–38. doi:10.1016/j.cellsig.2018.09.014.
   PubMed Web of Science ®Google Scholar
• Bueno MJ, Pérez De Castro I, Gómez De Cedrón M, et al. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell. 2008;13(6):496–506. doi:10.1016/j.ccr.2008.04.018.
   PubMed Web of Science ®Google Scholar
• Jiang N, Jiang X, Chen Z, et al. MiR-203a-3p suppresses cell proliferation and metastasis through inhibiting LASP1 in nasopharyngeal carcinoma. J Exp Clin Canc Res. 2017;36(1):138.
   PubMedGoogle Scholar
• Conde-Perez A, Gros G, Longvert C, et al. A caveolin-dependent and PI3K/AKT-independent role of PTEN in β-catenin transcriptional activity. Nat Commun. 2015;6(1):8093. doi:10.1038/ncomms9093.
   PubMedGoogle Scholar
• Mao L, Zhang Y, Mo W, Yu Y, Lu H. BANF1 is downregulated by IRF1-regulated microRNA-203 in cervical cancer. PLoS One. 2015;10(2):e117035. doi:10.1371/journal.pone.0117035.
   Web of Science ®Google Scholar
• Wang C, Wang X, Liang H, et al. miR-203 inhibits cell proliferation and migration of lung cancer cells by targeting PKCα. PLoS One. 2013;8(9):e73985. doi:10.1371/journal.pone.0073985.
   PubMed Web of Science ®Google Scholar
• Feber A, Xi L, Luketich JD, et al. MicroRNA expression profiles of esophageal cancer. J Thorac Cardiovasc Surg. 2008;135(2):255–260; discussion 260. doi:10.1016/j.jtcvs.2007.08.055.
   PubMed Web of Science ®Google Scholar
• Zhang LW, Wang B, Yang JX, Yang H. Circ-PRMT5 stimulates migration in esophageal cancer by binding miR-203. Eur Rev Med Pharmaco. 2020;24(19):9965–9972.
   PubMed Web of Science ®Google Scholar
• Wang T, Wang J, Ren W, et al. CircRNA-0008717 promotes cell proliferation, migration, and invasion by regulating miR-203/Slug in esophageal cancer cells. Ann Transl Med. 2020;8(16):999–999. doi:10.21037/atm-20-5205.
   PubMed Web of Science ®Google Scholar